213 related articles for article (PubMed ID: 17184940)
1. Crystallization rate of amorphous nifedipine analogues unrelated to the glass transition temperature.
Miyazaki T; Yoshioka S; Aso Y; Kawanishi T
Int J Pharm; 2007 May; 336(1):191-5. PubMed ID: 17184940
[TBL] [Abstract][Full Text] [Related]
2. Differences in crystallization rate of nitrendipine enantiomers in amorphous solid dispersions with HPMC and HPMCP.
Miyazaki T; Aso Y; Yoshioka S; Kawanishi T
Int J Pharm; 2011 Apr; 407(1-2):111-8. PubMed ID: 21277962
[TBL] [Abstract][Full Text] [Related]
3. Phase behavior of poly(vinylpyrrolidone) containing amorphous solid dispersions in the presence of moisture.
Rumondor AC; Marsac PJ; Stanford LA; Taylor LS
Mol Pharm; 2009; 6(5):1492-505. PubMed ID: 19634917
[TBL] [Abstract][Full Text] [Related]
4. Characterization of the molecular distribution of drugs in glassy solid dispersions at the nano-meter scale, using differential scanning calorimetry and gravimetric water vapour sorption techniques.
van Drooge DJ; Hinrichs WL; Visser MR; Frijlink HW
Int J Pharm; 2006 Mar; 310(1-2):220-9. PubMed ID: 16427226
[TBL] [Abstract][Full Text] [Related]
5. Molecular mobility-based estimation of the crystallization rates of amorphous nifedipine and phenobarbital in poly(vinylpyrrolidone) solid dispersions.
Aso Y; Yoshioka S; Kojima S
J Pharm Sci; 2004 Feb; 93(2):384-91. PubMed ID: 14705195
[TBL] [Abstract][Full Text] [Related]
6. Sudden rise of crystal growth rate of nifedipine near T(g) without and with polyvinylpyrrolidone.
Ishida H; Wu T; Yu L
J Pharm Sci; 2007 May; 96(5):1131-8. PubMed ID: 17455342
[TBL] [Abstract][Full Text] [Related]
7. Physical stability of the amorphous state of loperamide and two fragment molecules in solid dispersions with the polymers PVP-K30 and PVP-VA64.
Weuts I; Kempen D; Decorte A; Verreck G; Peeters J; Brewster M; Van den Mooter G
Eur J Pharm Sci; 2005 Jun; 25(2-3):313-20. PubMed ID: 15911228
[TBL] [Abstract][Full Text] [Related]
8. Role of molecular interaction in stability of celecoxib-PVP amorphous systems.
Gupta P; Thilagavathi R; Chakraborti AK; Bansal AK
Mol Pharm; 2005; 2(5):384-91. PubMed ID: 16196491
[TBL] [Abstract][Full Text] [Related]
9. Ability of different polymers to inhibit the crystallization of amorphous felodipine in the presence of moisture.
Konno H; Taylor LS
Pharm Res; 2008 Apr; 25(4):969-78. PubMed ID: 17520180
[TBL] [Abstract][Full Text] [Related]
10. Prediction of onset of crystallization in amorphous pharmaceutical systems: phenobarbital, nifedipine/PVP, and phenobarbital/PVP.
Caron V; Bhugra C; Pikal MJ
J Pharm Sci; 2010 Sep; 99(9):3887-900. PubMed ID: 20575050
[TBL] [Abstract][Full Text] [Related]
11. Development of fully amorphous dispersions of a low T(g) drug via co-spray drying with hydrophilic polymers.
Zhao M; Barker SA; Belton PS; McGregor C; Craig DQ
Eur J Pharm Biopharm; 2012 Nov; 82(3):572-9. PubMed ID: 22922419
[TBL] [Abstract][Full Text] [Related]
12. Solid dispersions of itraconazole and enteric polymers made by ultra-rapid freezing.
Overhoff KA; Moreno A; Miller DA; Johnston KP; Williams RO
Int J Pharm; 2007 May; 336(1):122-32. PubMed ID: 17184938
[TBL] [Abstract][Full Text] [Related]
13. The glass transition temperatures of amorphous trehalose-water mixtures and the mobility of water: an experimental and in silico study.
Simperler A; Kornherr A; Chopra R; Jones W; Motherwell WD; Zifferer G
Carbohydr Res; 2007 Aug; 342(11):1470-9. PubMed ID: 17511976
[TBL] [Abstract][Full Text] [Related]
14. Recrystallization of nifedipine and felodipine from amorphous molecular level solid dispersions containing poly(vinylpyrrolidone) and sorbed water.
Marsac PJ; Konno H; Rumondor AC; Taylor LS
Pharm Res; 2008 Mar; 25(3):647-56. PubMed ID: 17846870
[TBL] [Abstract][Full Text] [Related]
15. Miscibility of nifedipine and hydrophilic polymers as measured by (1)H-NMR spin-lattice relaxation.
Aso Y; Yoshioka S; Miyazaki T; Kawanishi T; Tanaka K; Kitamura S; Takakura A; Hayashi T; Muranushi N
Chem Pharm Bull (Tokyo); 2007 Aug; 55(8):1227-31. PubMed ID: 17666850
[TBL] [Abstract][Full Text] [Related]
16. Influence of different polymers on the crystallization tendency of molecularly dispersed amorphous felodipine.
Konno H; Taylor LS
J Pharm Sci; 2006 Dec; 95(12):2692-705. PubMed ID: 16892209
[TBL] [Abstract][Full Text] [Related]
17. Effect of polymer type on the dissolution profile of amorphous solid dispersions containing felodipine.
Konno H; Handa T; Alonzo DE; Taylor LS
Eur J Pharm Biopharm; 2008 Oct; 70(2):493-9. PubMed ID: 18577451
[TBL] [Abstract][Full Text] [Related]
18. Effect of physical properties of troglitazone crystal on the molecular interaction with PVP during heating.
Hasegawa S; Furuyama N; Yada S; Hamaura T; Kusai A; Yonemochi E; Terada K
Int J Pharm; 2007 May; 336(1):82-9. PubMed ID: 17178201
[TBL] [Abstract][Full Text] [Related]
19. Glass transition and time-dependent crystallization behavior of dehydration bioprotectant sugars.
Schebor C; Mazzobre MF; Buera Mdel P
Carbohydr Res; 2010 Jan; 345(2):303-8. PubMed ID: 19962131
[TBL] [Abstract][Full Text] [Related]
20. Investigating miscibility and molecular mobility of nifedipine-PVP amorphous solid dispersions using solid-state NMR spectroscopy.
Yuan X; Sperger D; Munson EJ
Mol Pharm; 2014 Jan; 11(1):329-37. PubMed ID: 24256090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
